| Nov 13 |
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
|
| Oct 22 |
BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
|
| Aug 1 |
BioSig intends to acquire Neuro-Kinesis’ assets
|
| Jul 31 |
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
|
| Jul 25 |
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024
|
| Jun 10 |
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
|
| May 30 |
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| May 30 |
BioSig Technologies slumps 18% on $3M equity sale
|
| May 30 |
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| May 21 |
BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders
|
